Edgewise Therapeutics (NASDAQ:EWTX) Downgraded to Sell Rating by Wall Street Zen

Edgewise Therapeutics (NASDAQ:EWTX) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Other equities research analysts also recently issued reports about the stock. Piper Sandler reissued an “overweight” rating on shares of Edgewise Therapeutics in a research report on Monday, February 9th. Stifel Nicolaus set a $25.00 price objective on Edgewise Therapeutics in a report on Thursday. Evercore restated an “outperform” rating and issued a $45.00 target price on shares of Edgewise Therapeutics in a report on Thursday. Wedbush lowered their target price on shares of Edgewise Therapeutics from $35.00 to $32.00 and set an “outperform” rating for the company in a report on Friday, November 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Edgewise Therapeutics in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $36.36.

Edgewise Therapeutics Stock Up 2.6%

NASDAQ:EWTX opened at $30.44 on Friday. Edgewise Therapeutics has a twelve month low of $10.60 and a twelve month high of $31.82. The company has a fifty day moving average of $27.62 and a 200-day moving average of $21.17. The firm has a market capitalization of $3.22 billion, a P/E ratio of -18.67 and a beta of 0.27.

Edgewise Therapeutics (NASDAQ:EWTX) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). On average, analysts anticipate that Edgewise Therapeutics will post -1.45 EPS for the current fiscal year.

Insider Activity

In related news, Director Badreddin Edris sold 115,471 shares of the company’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $29.44, for a total transaction of $3,399,466.24. Following the sale, the director directly owned 19,820 shares in the company, valued at approximately $583,500.80. This represents a 85.35% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 23.20% of the stock is currently owned by company insiders.

Institutional Trading of Edgewise Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in EWTX. Bessemer Group Inc. lifted its holdings in Edgewise Therapeutics by 1,170.3% during the 3rd quarter. Bessemer Group Inc. now owns 2,350 shares of the company’s stock worth $38,000 after purchasing an additional 2,165 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Edgewise Therapeutics during the 2nd quarter valued at $45,000. Jones Financial Companies Lllp bought a new stake in Edgewise Therapeutics during the first quarter valued at $47,000. Seven Fleet Capital Management LP bought a new position in Edgewise Therapeutics in the 4th quarter worth about $50,000. Finally, Steward Partners Investment Advisory LLC raised its holdings in shares of Edgewise Therapeutics by 23.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,854 shares of the company’s stock valued at $71,000 after acquiring an additional 550 shares in the last quarter.

Edgewise Therapeutics News Summary

Here are the key news stories impacting Edgewise Therapeutics this week:

• Positive Sentiment: Multiple near‑term clinical catalysts could drive upside: management flagged CIRRUS‑HCM 12‑week data for EDG‑7500 and Phase 1 healthy‑adult data for EDG‑15400 (with planned heart‑failure studies) expected in H1 2026, and pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy anticipated in Q4 2026. These readouts materially de‑risk the pipeline and are likely the main reason investors are buying the stock. PR Newswire: Q4 & Full Year 2025 Results
• Positive Sentiment: Company increased R&D investment in Q4, signaling management is funding those near‑term trials and pivotal work — a positive for long‑term value creation if the upcoming readouts are favorable. BizWest: R&D boost
• Neutral Sentiment: Analyst modeling: HC Wainwright published quarterly EPS forecasts for 2026 (Q1 -$0.43, Q2 -$0.47, Q3 -$0.51, Q4 -$0.60; full‑year -$1.45). These estimates reinforce expectations of continued operating losses as the company advances trials; they provide a near‑term earnings framework but don’t change the pipeline narrative. MarketBeat: HC Wainwright estimates
• Neutral Sentiment: Valuation discussion: recent coverage (e.g., Yahoo Finance) examines EWTX’s strong multi‑year returns and recent momentum, useful for investors assessing whether current share price already reflects upcoming catalysts. Yahoo Finance: Valuation piece
• Negative Sentiment: Q4 earnings miss and near‑term financial drag: Edgewise reported EPS of ($0.47) for the quarter, missing the consensus ($0.43). The combination of the miss and higher R&D spend increases short‑term risk and means more funding will likely be required before positive cash flow. Press Release: Q4 Results

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.